As Takeda Integrates Its Nycomed Acquisition, Europe Bears Brunt Of Job Cuts
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda is to close two R&D facilities in Germany and to cut commercial activities in the U.S., as it looks for cost savings from the 2011 acquisition of Nycomed.
You may also be interested in...
Nycomed US Plans Growth Through Acquisition
Now that Takeda has entered into a $13 billion deal to buy Nycomed, the U.S. affiliate, which isn't part of the deal, plans to grow sales by 10% annually through 2015.
Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
The deal, if confirmed, would boost Takeda's European and emerging markets presence, providing an additional €3.2 billion in revenues to help offset forthcoming patent expiries.
Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains
TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success